+31.5% · 90d
$4.09
+0.19 (+4.87%)
News
(1)April 2026
AGENUS secures $91M and reports strong clinical and commercial progress
AGENAGENUS INC
# 📜 What This Document Is 📄 This document is a Preliminary Proxy Statement for Agenus Inc.'s 2026 Annual Meeting of Stockholders. In simple terms, it's the company's formal "state of the union" report, explaining how the company has performed, detailing its leadership structure, and asking stockho
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%